Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS-28 CRP and key secondary endpoints were met. However, efficacy was numerically undifferentiated from peresolimab and the firm says rosnilimab “looks like a me-too in RA.” Confusion and questions around handing of the placebo group post double-blinded study period through week 12 raises questions about the veracity of week 14 data, adds the analyst, who keeps a Hold rating and $20 price target on AnaptysBio shares.